-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The global AI pharmaceutical landscape
The global AI pharmaceutical landscapeAI pharmaceutical companies conduct AI pharmaceutical research and development by providing outsourcing services for pharmaceutical companies and CROs, or independently promoting their own pipelines, trying to overcome problems in the fields of cancer, psychiatric diseases, cardiovascular and cerebrovascular diseases, liver, kidney, gastrointestinal diseases, and respiratory diseases, and discovering new drugs
.
The advantage of cooperating with data-rich pharmaceutical companies and CROs is that AI pharmaceutical companies can optimize and improve their algorithm models faster based on a large amount of high-quality data; The advantage of independent R&D is that companies can verify the effectiveness of
their algorithm models faster in a smaller size.
The two models are not in conflict, and leading companies can advance both outsourcing services and their own
pipelines.
As of Q3 2022, there were about 600 AI drug discovery companies worldwide, a year-on-year increase of 21.
6% (Q3,470 in 2021).
Among them, the United States, as a leading developed country, ranks first
in the world in the number of AI pharmaceutical companies.
In 2020, nearly 130 AI pharmaceutical startups were born, accounting for 54.
4% of the world; Two years later, the number reached 343, an increase of nearly threefold
.
Secondly, the number of AI pharmaceutical companies in Europe has soared in recent years, with a cumulative total of 150 in 2022, accounting for 25%
of the global total.
In 2020, there were just over 30 startups
in the region.
In addition, the number of related in Asia and the Middle East continued to grow, accounting for about 13%
of the total.
According to statistics, there are nearly 80 AI pharmaceutical-related companies in China, including Insilico, AccutarBio, Unknownjun, XtalPi, XingYao Technology, Wangshi Wisdom, Puri Benchmark, Xunbaihui Biotechnology, and
Woshi Technology.
Among them, Insilico, XtalPi and AccutarBio have developed rapidly and enjoy high overseas popularity
.
It is worth noting that compared with 2020, the number of AI pharmaceutical companies in the UK has decreased by 6%, and there are currently about 50; North America and Canada also saw a slight decline
.
Of the 28 leading AI pharmaceutical companies, 15 have gone public
.
Among them, there are 9 in the United States, 2 in the United Kingdom, and 1 each in Europe, Denmark, Switzerland and Canada
.
In terms of the number of pipelines and clinical progress, the top 3 are Landos
Biopharma（6/17）、Recursion（4/16）、Exscientia（3/26）
。
AI Pharma's financing in 2022
AI Pharma's financing in 2022AI has also attracted much attention
from the capital market in the field of drug research and development.
The data shows that from 2014 to 2018, the amount of investment in the global AI pharmaceutical field increased by 15 times
.
With the advent of the domestic innovative drug research and development boom, domestic AI pharmaceutical companies are increasingly gaining the favor
of the capital market.
According to incomplete statistics, in 2021, more than 20 domestic AI pharmaceutical companies won nearly 10 billion yuan in financing
.
Among them, Fengkun Intelligent completed a series A financing of more than 100 million yuan, Unknown Jun completed a series B financing of nearly 100 million US dollars, and Insilion completed a series C financing of 255 million US dollars
.
According to the McKinsey report, Chinese smart drug development companies are rising and keeping pace with global trends
.
Taking the top 20 AI pharmaceutical companies in the world for pre-IPO financing, for example, the number of companies from China accounts for one-third
.
At the same time, 29% of the total financing of these 20 companies came from China, and the financing situation of 29 domestic AI companies and related fields
in the first three quarters of 2022 is compiled here.
AI pharmaceutical financing from January to September 2022, sorted out by Star Wealth Research Institute
According to the above table, from January to September 2022, there were 29 domestic financing activities in the field of AI drug research and development, with a total amount of more than 3 billion yuan
.
From the perspective of R&D, AI pharmaceuticals are more innovative drugs assisting R&D, applying technologies such as "machine learning, natural language processing, and big data" to specific application scenarios in the pharmaceutical field (including but not limited to proteins, molecular drugs, gene therapy, and synthetic biology).
Relevant R&D personnel said: The main challenge of AI is how to use AI to a certain link of drug development, and it happens that the data form and algorithm in this link are seamlessly connected
.
The technical scope of AI-enabled pharmaceutical research is placed in the auxiliary stage, and multi-party cooperation
is required in technology adoption.
This part mainly focuses on drug adherence, predicting treatment outcomes, data analysis, case studies and disease diagnosis, so the technology development of AI pharmaceutical research is inevitably moving towards multimodal integration
.
Conclusion
ConclusionAs a rising star, the Chinese market seems to have more advantageous conditions
in AI pharmaceuticals.
On the one hand, the population base is huge and the scale of hospitals is considerable, which is more conducive to collecting big data
for training AI.
Secondly, a large number of pharmaceutical R&D contract outsourcing service institutions in China facilitate pharmaceutical companies to carry out multiple trials in parallel, and facilitate AI learning to compare different results
.
On the other hand, driven by the superposition of favorable factors such as policy support and market demand, the scale of China's AI drug R&D market will maintain a high growth in the short term, and in July 2021, CDE issued the "Clinical Value-oriented Guidelines for Clinical R&D of Antitumor Drugs", which further clarifies and improves the R&D positioning and marketing requirements
of domestic innovative drugs.
At the same time, the state has continuously introduced relevant plans for the artificial intelligence industry to encourage the integration
of artificial intelligence technology and the real economy.
In March 2019, the State Council issued the Guiding Opinions on Promoting the Deep Integration of Artificial Intelligence and the Real Economy, which further promoted the transformation of innovative achievements of AI technology and encouraged the coordinated development
of AI technology and industry.
The introduction of these core policies has become the core driving force
to promote the transformation of the AI pharmaceutical industry.
It can be seen that the threshold for innovative drug research and development is lowered, and the industry process is promoted, AI has taken a big step towards the goal, it is speculated that in the next 3-5 years, innovative drugs discovered by AI will go to the clinic, who will be the first to qualify?
